Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,435.75 27.21 0.17%
S&P 500 1,864.95 0.10 0.01%
NASDAQ 4,105.10 9.59 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Prescription for Success: Commercialization Efforts, Acquisitions and Enhanced Patent Protection - Research Report on PAREXEL



Prescription for Success: Commercialization Efforts, Acquisitions and Enhanced
    Patent Protection - Research Report on PAREXEL International, Ironwood
 Pharmaceuticals, Opko Health, Amarin Corporation, Progenics Pharmaceuticals

PR Newswire

NEW YORK, March 19, 2013

NEW YORK, March 19, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting PAREXEL
International Corporation (NASDAQ: PRXL), Ironwood Pharmaceuticals, Inc.
(NASDAQ: IRWD), Opko Health Inc. (NYSE: OPK), Amarin Corporation plc (ADR)
(NASDAQ: AMRN) and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

PAREXEL International Corporation Research Report

In the coming year, PAREXEL International hopes to benefit from its
acquisition of Liquent Inc., a provider of Regulatory Information Management
solutions. This is expected to strengthen the company's technology and
regulatory capabilities. The company notes that its healthy backlog of new
projects and strong flow of proposals will fuel revenue growth. Furthermore,
the company recently provided an update of its share repurchase program,
saying that the company expects to receive approximately 265,000 additional
shares of the company's common stock upon maturity of the accelerated share
repurchase program on March 26, 2013. So far, the company has paid $100
million under its repurchase programs. It also plans to repurchase an
additional $50 million worth of shares of its common stock. These are all
parts of the company's plans to achieve profitable growth and increase
shareholder value. The Full Research Report on PAREXEL International
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wallstsource.com/r/full_research_report/037f_PRXL]

Ironwood Pharmaceuticals, Inc. Research Report

Ironwood Pharmaceuticals has been impressing analysts due to Linzess sales.
The company's shares surged 6 percent after Credit Suisse analyst Catherine
Arnold upgraded the company from Neutral to Outperform and significantly
raised its price target from $15 to $24. The analyst notes that a survey from
her firm of roughly 100 physicians suggest great demand for Linzess, a
treatment for irritable bowel syndrome. She also notes that feedback from
Linzess users is generally positive and physicians plan to increase
prescribing the product in the future. The Bank of America also raised its
price target noting the increased number of prescriptions in February. In the
future, the company will continue to focus on the successful commercialization
of Linzess while also exploring development opportunities to broaden the
product in other indications and geographies. The drug will be launched as
CONSTELLA in Europe during the first half of 2013. The Full Research Report on
Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wallstsource.com/r/full_research_report/d5cb_IRWD]

Opko Health Inc. Research Report

Opko Health recently announced a strategic pooling of its assets in the field
of RNA interface (RNAi). In the terms of the agreement, RXi Pharmaceuticals
Corporation will acquire all of Opko's RNAi-related assets, including its
patent portfolio. As payment, RXi will issue to Opko 50 million shares of its
common stock and will make milestone payments up to $50 million per product
that was developed using Opko intellectual property. RXi will also make
royalty payments to OPKO upon commercialization of these products. This will
help provide steady inflows as Opko acquires assets from other companies like
its recent purchase of two phase 3 products of Cytochroma and a Brazilian
pharmaceutical company Silicon Comercio. The phase 3 products may strengthen
the company's pipeline while Silicon Comercio may help the company penetrate a
new high-growth market. The Full Research Report on Opko Health Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wallstsource.com/r/full_research_report/cb42_OPK]

Amarin Corporation plc (ADR) Research Report

Earlier this year, Amarin filed a Supplemental New Drug Application (sNDA) for
Vascepa ANCHOR indication with the FDA and expects action date on the
application before 2013. Furthermore, the company has filed more applications
to expand its patents, including patent applications related to Vascepa in
other countries. Expanding the patent protection for Vascepa helps the product
compete in the triglyceride lowering market. The company aims to protect the
commercial potential of Vascepa beyond 2030. The Full Research Report on
Amarin Corporation plc (ADR) - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wallstsource.com/r/full_research_report/79f9_AMRN]

Progenics Pharmaceuticals, Inc. Research Report

Progenics shares spiked 29 percent after the company crushed Wall Street
expectations with a loss of 1 cent per share, as compared to a net loss of 32
cents per diluted share in the 2011 period. This strong result is an effect of
higher revenue along with reduced expenses. In the future, Progenics expects
to benefit from its out-licensed C. difficile preclinical program of $5
million upfront payment received last January with potential future milestones
and royalties. Its acquisition of Molecular Insight Pharmaceuticals is also
expected to help the company expand its oncology pipeline with diagnostic and
small molecule candidates. Full Research Report on Progenics Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.wallstsource.com/r/full_research_report/cd12_PGNX]

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Joe Thomas
Email: press@WallStSource.com
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement